| pubmed-article:15385121 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15385121 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15385121 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15385121 | pubmed:dateCreated | 2004-9-23 | lld:pubmed |
| pubmed-article:15385121 | pubmed:abstractText | The efficacy and toxicity of combined therapy with irinotecan (CPT-11) plus mitomycin-C (MMC) were evaluated in patients with advanced or recurrent squamous cell carcinoma (SCC) of the uterine cervix. | lld:pubmed |
| pubmed-article:15385121 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15385121 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15385121 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15385121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15385121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15385121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15385121 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15385121 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15385121 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:FushikiHirosh... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:IzumiRikuichi... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:NishidaMasato... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:NishimuraRyui... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:HasegawaKazuo... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:UmesakiNaohik... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:TanakaTetsuji... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:YamamotoKaich... | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:FujiiTuneoT | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:TakizawaKenK | lld:pubmed |
| pubmed-article:15385121 | pubmed:author | pubmed-author:Japan... | lld:pubmed |
| pubmed-article:15385121 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15385121 | pubmed:volume | 95 | lld:pubmed |
| pubmed-article:15385121 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15385121 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15385121 | pubmed:pagination | 127-32 | lld:pubmed |
| pubmed-article:15385121 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:meshHeading | pubmed-meshheading:15385121... | lld:pubmed |
| pubmed-article:15385121 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15385121 | pubmed:articleTitle | Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. | lld:pubmed |
| pubmed-article:15385121 | pubmed:affiliation | Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan. umesaki@wakayama-med.ac.jp | lld:pubmed |
| pubmed-article:15385121 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15385121 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15385121 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15385121 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
